| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c9faf891bdd318970bba39c126b05599
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_461514df460e0cdd5644e86ba60adbf7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7e0e42cba4bee6c48312821708b5d3a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2420-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-04 |
| filingDate |
2017-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94cdb89427589c8688c50ce1db93aed9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_609cfc45f73afbcf13faa8ee842a22f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6643cbd542475a3b0a934cd8bdf29fb |
| publicationDate |
2022-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-3072163-C |
| titleOfInvention |
Disintegrin variants and uses thereof |
| abstract |
Disclosed herein are disintegrin variants, and methods for suppressing or inhibiting platelet aggregation in a subject in need thereof. The method includes administering to the subject in need thereof an effective amount of the present disintegrin variant to alleviate or ameliorate symptoms associated with diseases, disorders, and/or conditions resulted from platelet aggregation. According to preferred embodiments, the present disintegrain variant is applied as a coating on an implantable device, such as a stent or a catheter. |
| priorityDate |
2017-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |